HIB vaccination

Vaccination intended to prevent H influenzae type B infection, which causes meningitis and epiglottitis with airway obstruction Dosing 2, 4, 6 months of age, followed by a booster at 12-15 months of age Adverse reactions Rare

Mentioned in ?

References in periodicals archive ?

Beginning in 1989, countries of the European Union and European Economic Area (EU/EEA) began introducing conjugate Hib vaccination into their routine national immunization programs; most countries introduced the vaccine before the year 2000.

Epidemiology of invasive Haemophilus influenzae disease, Europe, 2007-2014

By 2006, when WHO recommended Hib vaccine in all routine infant immunization schedules, 108 countries, accounting for >55% of the world's children, had introduced routine Hib vaccination (7).

Status of new vaccine introduction--worldwide, September 2016

* Limit Haemophilus influenzae b (Hib) to one dose for all children and adolescents with no previous history of Hib vaccination.

Clinical guidelines: vaccination of the immunocompromised

The Hib vaccination is not recommended for HIV-infected adults.

Committee affirms update of 1993 Hib statement

HibMenCY is safe and immunogenic and may be administered to infants to complete the routine Hib vaccination series.

Vaccine update: the latest from ACIP ACIP has combined 2 vaccine schedules into a single schedule for infants, children, and adolescents. It also recommends the Tdap vaccine for those [greater than or equal to]65 years and the pneumococcal conjugate vaccine for adults at high risk

GSK said that MenHibrix was developed to align with the Centres for Disease Control and Prevention's recommended infant immunisation schedule for Hib vaccination and to allow for vaccination against meningococcal groups C & Y without adding additional shots.

GSK announces FDA approval for MenHibrix

A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease.

One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18-19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine

Black et al (14) have estimated 31,607 deaths attributable to meningitis in India after taking into account cases currently prevented by the Hib vaccination (Hib vaccine is available and used in India).

Introducing pentavalent vaccine in EPI in India: a counsel for prudence in interpreting scientific literature

(1) In countries with routine Hib vaccination, Hib is no longer the most important cause of bacterial meningitis in children.

Bacterial meningitis in the era of paediatric vaccination against the encapsulated pathogens: bacterial meningitis is still prevalent worldwide in spite of effective vaccines

By 2004, a total of 134 of 165 developing countries had introduced hepatitis B vaccination into their national immunization schedules, and 63 had introduced Hib vaccination; however, coverage levels have stagnated or remain suboptimal in many countries.

Vacuna liquida combinada DTPw-HepB-Hib como dosis de refuerzo en infantes de El Salvador

Even though there was a Hib vaccination shortage at the time, none of the children were unvaccinated due to the shortage.